Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
First-in-class SK channel inhibition proof of mechanism achieved
First new approach to treating Atrial Fibrillation for 20 years
Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm.
